Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for DRMA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2021. Start Trial.
Date Value
June 30, 2026 3.488M
March 31, 2026 6.413M
December 31, 2025 6.223M
September 30, 2025 3.960M
June 30, 2025 5.614M
March 31, 2025 7.301M
December 31, 2024 1.561M
September 30, 2024 4.741M
June 30, 2024 3.318M
March 31, 2024 3.808M
December 31, 2023 6.355M
Date Value
September 30, 2023 6.407M
June 30, 2023 8.03M
March 31, 2023 8.088M
December 31, 2022 6.022M
September 30, 2022 7.471M
June 30, 2022 9.66M
March 31, 2022 7.852M
December 31, 2021 10.11M
September 30, 2021 12.49M
June 30, 2021 -0.5058M
March 31, 2021 0.712M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. 137.28M
Perspective Therapeutics, Inc. 323.86M
MiMedx Group, Inc. 216.00M
ABVC BioPharma, Inc. 10.29M
Endonovo Therapeutics, Inc. -30.05M

Shareholders Equity (Quarterly) Related Metrics